BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18(41): 5833-5838 [PMID: 23139598 DOI: 10.3748/wjg.v18.i41.5833]
URL: https://www.wjgnet.com/1007-9327/full/v18/i41/5833.htm
Number Citing Articles
1
Masahiro Iizuka, Takeshi Etou, Makoto Kumagai, Atsushi Matsuoka, Yuka Numata, Shiho Sagara. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative ColitisInternal Medicine 2017; 56(20): 2705 doi: 10.2169/internalmedicine.8428-16
2
Yoh Ishiguro, Toshihide Ohmori, Ken Umemura, Masahiro Iizuka. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort studyTherapeutic Apheresis and Dialysis 2021; 25(4): 502 doi: 10.1111/1744-9987.13594
3
Farah Yasmin, Hala Najeeb, Unaiza Naeem, Abdul Moeed, Thoyaja Koritala, Salim Surani. Apheresis: A cell-based therapeutic tool for the inflammatory bowel diseaseWorld Journal of Clinical Cases 2022; 10(21): 7195-7208 doi: 10.12998/wjcc.v10.i21.7195
4
Hiroshi Katayama. Rheumatoid arthritis: Development after the emergence of a chemokine for neutrophils in the synoviumBioEssays 2021; 43(10) doi: 10.1002/bies.202100119
5
Emre Gerçeker, Hakan Yüceyar, Elmas Kasap, Ufuk Demirci, Burcu Ceren Ekti, İsmet Aydoğdu, Mine Miskioğlu. Treatment of inflammatory bowel disease by leukocytapheresisTransfusion and Apheresis Science 2017; 56(3): 421 doi: 10.1016/j.transci.2017.03.016